Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

Jose Pablo Leone, Kyrre E. Emblem, Michelle Weitz, Rebecca S. Gelman, Bryan P. Schneider, Rachel A. Freedman, Jerry Younger, Marco C. Pinho, A. Gregory Sorensen, Elizabeth R. Gerstner, Gordon Harris, Ian E. Krop, Daniel Morganstern, Jessica Sohl, Jiani Hu, Elizabeth Kasparian, Eric P. Winer, Nancy U. Lin

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: We aimed to examine the safety and efficacy of bevacizumab and carboplatin in patients with breast cancer brain metastases. Methods: We enrolled patients with breast cancer and > 1 measurable new or progressive brain metastasis. Patients received bevacizumab 15 mg/kg intravenously (IV) on cycle 1 day 1 and carboplatin IV AUC = 5 on cycle 1 day 8. Patients with HER2-positive disease also received trastuzumab. In subsequent cycles, all drugs were administered on day 1 of each cycle. Contrast-enhanced brain MRI was performed at baseline, 24–96 h after the first bevacizumab dose (day + 1), and every 2 cycles. The primary endpoint was objective response rate in the central nervous system (CNS ORR) by composite criteria. Associations between germline VEGF single nucleotide polymorphisms (rs699947, rs2019063, rs1570360, rs833061) and progression-free survival (PFS) and overall survival (OS) were explored, as were associations between early (day + 1) MRI changes and outcomes. Results: Thirty-eight patients were enrolled (29 HER2-positive, 9 HER2-negative); all were evaluable for response. The CNS ORR was 63% (95% CI, 46–78). Median PFS was 5.62 months and median OS was 14.10 months. As compared with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, patients with ECOG PS 1–2 had significantly worse PFS and OS (all P < 0.01). No significant associations between VEGF genotypes or early MRI changes and clinical outcomes were observed. Conclusions: The combination of bevacizumab and carboplatin results in a high rate of durable objective response in patients with brain metastases from breast cancer. This regimen warrants further investigation. Trial registration: NCT01004172. Registered 28 October 2009.

Original languageEnglish (US)
Article number131
JournalBreast Cancer Research
Volume22
Issue number1
DOIs
StatePublished - Dec 2020

Keywords

  • Bevacizumab
  • Brain metastases
  • Breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases'. Together they form a unique fingerprint.

Cite this